The round was led by KKR and OMX Ventures, with additional participation from ARTIS Ventures and Lansdowne Partners, SALT, DeciBio Ventures, and Axial. San Diego, California and London, UK, 25 July 2022 – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced its launch with $55 million in seed financing. Five product companies have been incorporated to date.Innovative hub-and-spoke business model separates technology development from product development, leveraging Replay’s technologies within discrete product companies.Company is led and supported by a world-class team of academics, entrepreneurs, and industry experts.Replay’s genomic medicine toolkit encompasses a portfolio of disruptive platform technologies to write and deliver big DNA, including a high payload capacity HSV delivery platform, a hypoimmunogenic cell therapy platform, and a proprietary genome writing platform.KKR and OMX Ventures lead $55 million seed funding round.
0 kommentar(er)
